Suppr超能文献

吸入丙酸倍氯米松对哮喘患者诱导痰中过氧亚硝酸盐抑制活性的影响。

Effect of inhaled beclomethasone dipropionate on peroxynitrite inhibitory activity in induced sputum from asthmatic patients.

作者信息

Kanazawa Hiroshi, Nomura Saeko, Hirata Kazuto, Yoshikawa Junichi

机构信息

Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan.

出版信息

Chest. 2003 Nov;124(5):1755-61. doi: 10.1378/chest.124.5.1755.

Abstract

STUDY OBJECTIVES

We recently found that peroxynitrite inhibitory activity in induced sputum was significantly lower in asthmatic patients than in normal control subjects. Current guidelines recommend inhaled corticosteroids as first-line control therapy in asthma. Therefore, this study was designed to examine the effect of inhaled beclomethasone dipropionate (BDP) on peroxynitrite inhibitory activity in induced sputum from asthmatic patients.

DESIGN

Interventional study.

SETTING

University hospital.

PATIENTS

Twenty-one asthmatic patients and 10 age-matched, normal control subjects.

INTERVENTIONS

Inflammatory indexes in induced sputum were examined in all study subjects, and peroxynitrite inhibitory activity was also assayed by monitoring rhodamine formation. For 8 weeks after the first sputum induction, BDP 400 microg bid, was administered to all asthmatic patients and sputum induction was repeated.

MEASUREMENTS AND RESULTS

Nitrite and nitrate levels in induced sputum were significantly higher in asthmatic patients (1,121 micro mol/L [SD, 205 micro mol/L], p < 0.0001) than in normal control subjects (642 micromol/L [SD, 137 micromol/L]). In contrast, peroxynitrite inhibitory activity in induced sputum was significantly lower in asthmatic patients (50.0% [SD, 25.7%], p < 0.0001) than in normal control subjects (93.0% [SD, 3.6%]). After 8 weeks of BDP therapy, nitrite and nitrate levels were significantly decreased (847 micromol/L [SD, 143 micromol/L], p < 0.0001) and peroxynitrite inhibitory activity was increased (73.9% [SD, 19.2%], p = 0.0005). Moreover, the increase in peroxynitrite inhibitory activity from before to after BDP therapy was significantly correlated with decrease in nitrite and nitrate levels (r = 0.79, p = 0.0004). We also found the significant relationship between increase in peroxynitrite inhibitory activity in induced sputum and increase in FEV(1) percentage of predicted after BDP therapy (r = 0.68, p = 0.0023).

CONCLUSIONS

Large amounts of peroxynitrite, which are exaggerated in acute asthma attacks, might overwhelm endogenous antioxidant defenses. However, inhaled corticosteroid therapy enhanced antioxidant activity against peroxynitrite, and therefore might reduce the susceptibility to peroxynitrite-induced injury in asthmatic airways.

摘要

研究目的

我们最近发现,哮喘患者诱导痰中的过氧亚硝酸盐抑制活性显著低于正常对照受试者。当前指南推荐吸入性糖皮质激素作为哮喘的一线控制治疗药物。因此,本研究旨在探讨吸入丙酸倍氯米松(BDP)对哮喘患者诱导痰中过氧亚硝酸盐抑制活性的影响。

设计

干预性研究。

地点

大学医院。

患者

21例哮喘患者和10例年龄匹配的正常对照受试者。

干预措施

对所有研究对象检测诱导痰中的炎症指标,并通过监测罗丹明形成来测定过氧亚硝酸盐抑制活性。在首次诱导痰后8周内,所有哮喘患者每天两次吸入400μg BDP,并再次进行痰诱导。

测量与结果

哮喘患者诱导痰中的亚硝酸盐和硝酸盐水平(1,121μmol/L[标准差,205μmol/L],p<0.0001)显著高于正常对照受试者(642μmol/L[标准差,137μmol/L])。相比之下,哮喘患者诱导痰中的过氧亚硝酸盐抑制活性(50.0%[标准差,25.7%],p<0.0001)显著低于正常对照受试者(93.0%[标准差,3.6%])。BDP治疗8周后,亚硝酸盐和硝酸盐水平显著降低(847μmol/L[标准差,143μmol/L],p<0.0001),过氧亚硝酸盐抑制活性增加(73.9%[标准差,19.2%],p = 0.0005)。此外,BDP治疗前后过氧亚硝酸盐抑制活性的增加与亚硝酸盐和硝酸盐水平的降低显著相关(r = 0.79,p = 0.0004)。我们还发现诱导痰中过氧亚硝酸盐抑制活性的增加与BDP治疗后预计FEV(1)百分比的增加之间存在显著相关性(r = 0.68,p = 0.0023)。

结论

大量过氧亚硝酸盐在急性哮喘发作时会增加,可能会超过内源性抗氧化防御能力。然而,吸入性糖皮质激素治疗可增强对过氧亚硝酸盐 的抗氧化活性,因此可能降低哮喘气道对过氧亚硝酸盐诱导损伤的易感性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验